Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging.

FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy. Click here to find out why KALV is a Strong Buy.

KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral treatment for a type of hereditary swelling disorder, sending its shares ...

Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the ...